Q2 25 EPS
$-0.41
MISS 16.05%
Est. $-0.35
Q2 25 Revenue
$19.2M
BEAT +24.96%
Est. $15.4M
vs S&P Since Q2 25
-52.3%
TRAILING MARKET
RXRX -33.7% vs S&P +18.6%
Market Reaction
Did RXRX Beat Earnings? Q2 2025 Results
Recursion Pharmaceuticals delivered a mixed second quarter, posting revenue that cleared expectations by a wide margin while its bottom line fell short of analyst forecasts. The Salt Lake City-based AI drug discovery company reported Q2 2025 revenue … Read more Recursion Pharmaceuticals delivered a mixed second quarter, posting revenue that cleared expectations by a wide margin while its bottom line fell short of analyst forecasts. The Salt Lake City-based AI drug discovery company reported Q2 2025 revenue of $19.22 million, a 33.5% jump from the year-ago period and 24.96% ahead of the $15.38 million consensus, driven in part by a $7.00 million Sanofi milestone payment representing the fourth partnered program to reach a discovery milestone in 18 months. Earnings per share, however, came in at -$0.41, missing the -$0.35 consensus estimate by 16.05%, as the net loss widened to $171.90 million largely on costs tied to the November 2024 Exscientia business combination and a $22.70 million non-cash Tempus data collaboration charge. Despite the earnings miss, shares moved higher in pre-market trading, with investors appearing to focus on the company's improving cost trajectory; management guided for 2025 cash burn below $450.00 million and projected a roughly 35% reduction in pro forma operating expenses from 2024 to 2026, with cash runway extending into Q4 2027.
Key Takeaways
- • Revenue increase driven by collaboration agreement milestones including $7 million Sanofi milestone payment
- • $28.6 million R&D tax credit received in first half of 2025
- • Increased R&D and G&A expenses primarily from Exscientia business combination completed November 2024
- • $22.7 million non-cash expense recognized for Tempus patient-centric multimodal oncology data
RXRX YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
“The power of our platform not only allows us to discover and develop potential new medicines, but also gives us insights on patient populations to target that would be challenging using traditional methods. In discovery, we're deploying advanced models like Boltz-2 to rapidly design ligands for high-value targets. State of the art platform capabilities helped us drive our fourth partnered discovery milestone with Sanofi this quarter, reflecting tangible momentum across our joint pipeline. We are leveraging these and other improvements to the Recursion OS to not only accelerate and improve our funnel of new programs, but also execution of later stage programs in our pipeline like RBM39 and CDK7.”
— Chris Gibson, Q2 2025 Earnings Press Release
RXRX Earnings Trends
RXRX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
RXRX EPS Trend
Earnings per share: estimate vs actual
RXRX Revenue Trend
Quarterly revenue: estimate vs actual
RXRX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.26 | $-0.22 | +14.43% | $6.5M | -58.98% |
| Q4 25 BEAT FY | $-0.32 | $-0.21 | +33.35% | $35.5M | +44.71% |
| FY Full Year | $-1.60 | $-1.44 | +10.08% | $74.7M | +21.21% |
| Q3 25 BEAT | $-0.38 | $-0.36 | +5.69% | $5.2M | -73.27% |
| Q2 25 MISS | $-0.35 | $-0.41 | -16.05% | $19.2M | +24.96% |
| Q1 25 BEAT | $-0.52 | $-0.50 | +3.10% | $14.7M | -18.46% |